Physician profile
Seth Mobley
NPI 1891311254
$2,181.17
in general payments reported to CMS, 2019-2025
22 companies · $949 in 2025
The $949 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $239 · 2024: $993 · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,181.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $512.13 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $194.38 | 2023-2025 | |
| Lilly USA, LLC | $171.42 | 2023-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $157.36 | 2023-2025 | Veozah |
| Novo Nordisk INC | $140.19 | 2024-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $136.60 | 2023-2025 | |
| Exact Sciences Corporation | $132.05 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $129.52 | 2023-2025 | Otezla, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.99 | 2023-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $93.99 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.68 | 2024-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $64.41 | 2023-2024 | Xarelto |
| Dexcom, INC. | $44.90 | 2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $42.77 | 2023-2024 | Trelegy Ellipta |
| Ironshore Pharmaceuticals INC. | $32.74 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $25.97 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $25.59 | 2025 | Rexulti |
| Abbvie INC. | $23.43 | 2025 | |
| Abbott Laboratories | $21.54 | 2025 | Freestyle Libre |
| Dynavax Technologies Corporation | $19.27 | 2024 | Heplisav-B |
| Exeltis, USA INC. | $17.19 | 2024 | Slynd |
| Sumitomo Pharma America, INC. | $15.05 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Mobley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.